论文部分内容阅读
目的研究支气管哮喘合并反复呼吸道感染应用兰菌净治疗的临床效果,并进一步探讨其使用安全性。方法选择46例支气管哮喘并发反复呼吸道感染患儿,将其按照随机原则分成研究组与对照组,各23例。研究组给予患儿使用兰菌净舌下滴入治疗,对照组则给予患儿应用安慰剂舌下滴入治疗。对两组患儿支气管哮喘并反复呼吸道感染症状进行对比分析,同时观察比较两组患儿的血清IgA水平以及唾液sIgA水平(检测方法选择单向免疫扩散方法),并对两组患儿可能出现的不良反应情况进行分析。结果与对照组相比较,研究组发热天数以及呼吸道感染次数均明显减少,差异有统计学意义(P﹤0.05),且哮喘发作天数、抗生素使用时间也有显著减少(P﹤0.05)。通过治疗后,研究组血清IgA水平较治疗前有所升高(P﹤0.05),而唾液sIgA水平治疗后的1～3个月与治疗前相比有显著升高(P﹤0.05),但在治疗后第6个月,与治疗前相比,差异无统计学意义(P﹥0.05)。对照组治疗前后相比,血清IgA及唾液sIgA水平无明显变化(P﹥0.05)。两组之间不良反应发生率相比,差异无统计学意义(P﹥0.05)。结论应用兰菌净对预防支气管哮喘合并反复呼吸道感染效果明显,且有较好的安全性,便于使用,值得广泛推广。
Objective To study the clinical effect of LanZhiJing treatment of bronchial asthma combined with recurrent respiratory tract infection and to further explore its safety. Methods Forty-six children with recurrent respiratory tract infection of bronchial asthma were randomly divided into study group and control group, with 23 cases in each group. The study group given to children with bacterial vaginosis drip treatment, while the control group was given to children with placebo sublingual drip treatment. The two groups of children with bronchial asthma and recurrent respiratory tract infection were compared, at the same time observe the two groups of children with serum IgA levels and saliva sIgA levels (detection method selection unidirectional immunodiffusion method), and the two groups of children may appear Adverse reactions were analyzed. Results Compared with the control group, the days of fever and the number of respiratory infections in the study group were significantly decreased (P <0.05), and the days of asthma attack and the duration of antibiotics were also significantly reduced (P <0.05). After treatment, the level of serum IgA in the study group was significantly higher than that before treatment (P <0.05), while salivary sIgA level was significantly increased from 1 to 3 months after treatment (P <0.05) At the 6th month after treatment, there was no significant difference between before and after treatment (P> 0.05). There was no significant difference in serum IgA and salivary sIgA levels between the two groups before and after treatment (P> 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusions The application of Lanshi Jing has obvious effect on preventing bronchial asthma with recurrent respiratory tract infection, and has good safety and ease of use, which is worth widely popularizing.